Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00097708
Other study ID # JZP 04-001-01
Secondary ID
Status Completed
Phase Phase 3
First received November 29, 2004
Last updated October 1, 2014
Start date November 2004
Est. completion date December 2005

Study information

Verified date October 2014
Source Jazz Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether an experimental anti-anxiety medication is effective in the treatment of Generalized Anxiety Disorder.


Description:

Protocol 04-001-01

The primary objective of the study is to assess, under controlled conditions, the safety and efficacy of an experimental anti-anxiety medication relative to placebo in subjects with generalized anxiety disorder (GAD).

The secondary objective of the study is to study algorithms for discontinuation of an experimental anti-anxiety medication.

Recruiting: Participants are currently being recruited and enrolled.


Recruitment information / eligibility

Status Completed
Enrollment 511
Est. completion date December 2005
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Subjects 18 to 65 years of age will be eligible to participate if they satisfy the DSM-IV-TR criteria for the diagnosis of GAD.

Exclusion Criteria:

- No other primary psychiatric diagnosis besides GAD.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
experimental anti-anxiety drug


Locations

Country Name City State
United States Crest Clinical Trials, Inc. Anaheim California
United States FutureSearch Trials Austin Texas
United States Pharmasite Research, Inc. Baltimore Maryland
United States Northwest Clinical Research Center Bellevue Washington
United States McLean Hospital Belmont Massachusetts
United States Southwesten Research, Inc. Beverly Hills California
United States Birmingham Research Group, Inc. Birmingham Alabama
United States Radiant Research Boise Idaho
United States Alpine Clinical Research Center Boulder Colorado
United States Florida Clinical Research Center Bradenton Florida
United States Social Psychiatry Research Institute Brooklyn New York
United States Southwestern Research Institute Burbank California
United States Southeast Health Consultants, LLC Charleston South Carolina
United States CNS Research Institute (CRI) Clementon New Jersey
United States Research Across America Dallas Texas
United States Midwest Clinical Research Center Dayton Ohio
United States ACT Clinical Research DeLand Florida
United States University Clinical Research DeLand, Inc. DeLand Florida
United States Oregon Center for Clinical Investigations, Inc. Eugene Oregon
United States Comprehensive Neuroscience of Northern Virginia Falls Church Virginia
United States Sarkis Clinical Trials Gainsville Florida
United States Clinical Neuroscience Solutions, Inc. Jacksonville Florida
United States ClinSearch, Inc. Kenilworth New Jersey
United States R/D Clinical Research, Inc. Lake Jackson Texas
United States Atlanta Institute of Medicine and Research Marietta Georgia
United States Suburban Research Associates Media Pennsylvania
United States CNS, Inc. Memphis Tennessee
United States New Orlean Medical Institute Metairie Louisiana
United States Dominion Clinical Research, Inc. Midlothian, Virginia
United States Clinical Research Associates, Inc. Nashville Tennessee
United States New Britain General Hospital New Britain Connecticut
United States American Medical Research, Inc. Oak Brook Illinois
United States IPS Research Company Oklahoma City Oklahoma
United States Clinical Neuroscience Solutions, Inc. Orlando Florida
United States Peak Medical Research, LLC Owensboro Kentucky
United States CNS Research Institute Philadelphia Pennsylvania
United States Princeton Medical Institute Princeton New Jersey
United States Pivotal Research Centers - Detroit Royal Oak Michigan
United States Lifetree Clinical Research Salt Lake City Utah
United States University of California - San Diego - Dept of Psychiatry San Diego California
United States Clinical Innovations Santa Ana California
United States Brentwood Research Institute Shreveport Louisiana
United States MedClin Research St. Louis Missouri
United States Meridien Research St. Petersburg Florida
United States Stanford University Medical Center Stanford California
United States Institute of Research in Psychiatry Tampa Florida
United States Neurology and Neuroscience Center of Ohio Toledo Ohio
United States Laureate Psychiatric Clinic and Hospital Tulsa Oklahoma
United States Diablo Clinical Research, Inc. Walnut Creek California
United States Janus Center for Psychiatric Research West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Jazz Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in HAM-A Total Score Hamilton Anxiety Rating Scale (HAM-A). Each of 14 symptoms categories is rated from 0=not present to 4=very severe. Numbers for all categories are summed to produce the total score. Total score ranges from 0=anxiety symptoms not present to 56=very severe anxiety symptoms across all 14 categories. Baseline to week 8 No
See also
  Status Clinical Trial Phase
Recruiting NCT06038721 - Unified Protocol: Community Connections N/A
Not yet recruiting NCT03224845 - Courageous Parents, Courageous Children N/A
Completed NCT02096783 - Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer N/A
Completed NCT02145429 - Preventing Depression in Late Life: A Model for Low and Middle Income Countries N/A
Completed NCT00794456 - Association of Passiflora Incarnata L; Crataegus Oxyacantha L and Salix Alba L. on Mild and Moderate Anxiety Phase 3
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A
Completed NCT00252343 - Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder Phase 3
Not yet recruiting NCT05867823 - OcupApp: Occupational Self-analysis Intervention Through an Mobile Application N/A
Recruiting NCT04562324 - Efficacy of Electroencephalography (EEG) Neurofeedback (NF) for the Treatment of Anxiety Disorder N/A
Recruiting NCT05989451 - Adaptation of Individual Dialectical Behavior Therapy Intervention for Transdiagnostic Treatment of Emotional Disorders N/A
Not yet recruiting NCT05488418 - Clinical Study of Biomarkers of Stress Resilience: Role of ELK1 and GPR56 N/A
Not yet recruiting NCT03608449 - Doing More With Less": Optimizing Psychotherapeutic Services in the Mental Health System N/A
Completed NCT03400397 - An Effectiveness Study of the Cool Kids Programme N/A
Completed NCT00025844 - Fear Conditioning Using Computer-Generated Virtual Reality N/A
Completed NCT02579928 - Ketamine Infusion for Adolescent Depression and Anxiety Phase 4
Completed NCT02270073 - The Process Outcome Mindfulness Effects in Trainees (PrOMET)-Study N/A
Terminated NCT03764644 - Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders N/A
Completed NCT01425619 - The Effect of Medical Clowns and Topical Anesthetic Cream on Pain and Anxiety in Children Undergoing Allergy Skin Tests N/A
Completed NCT01721824 - The Effect of IPS-MA- A Modified Early Supported Employment Intervention for Individuals With Mood or Anxiety Disorders N/A
Completed NCT01730625 - Augmenting Effects of ABMT on CBT in Anxious Children: A Randomized Clinical Trial N/A